Shanghai Pharmaceuticals’ Rivaroxaban Tablets Receive Singapore Drug Registration Certificate
February 27, 2026
Source: drugdu
31
Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Singapore Food and Drug Administration (HSA), and the drug has been approved for marketing.
Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness.
In May 2025, Changzhou Pharmaceutical Factory's rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration, and in October 2025, it obtained a drug registration certificate in Malaysia.
The approval of rivaroxaban tablets in three strengths (10mg, 15mg, and 20mg) by the Singapore Food and Drug Administration signifies that the drug is now qualified for sale in Singapore. This will have a positive impact on the company's expansion into overseas markets and will accumulate valuable experience.
https://bydrug.pharmcube.com/news/detail/8b3610576d85a2d8b0b8dd78ba5bb5da
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Boehringer Ingelheim’s “Zonartinib” Receives FDA Approval for Treatment-naïve NSCLC February 27, 2026
- Marketing application for recombinant anti-IL-4Rα humanized monoclonal antibody injection accepted February 27, 2026
- Genrix Bio’s marketing application for talicibazine injection for the treatment of adult seasonal allergic rhinitis has been accepted. February 27, 2026
- 13.8 billion! Leading domestic imaging equipment manufacturer sees significant revenue growth. February 27, 2026
- IL-4R antibody submitted for market approval February 27, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
